Conmed Corporation (CNMD) fundamentals score
• the ability to advance its product lines, including challenges and uncertainties inherent in product research and development, and the uncertain impact, outcome and cost of ongoing and future clinical trials and market studies;
Electromedical & Electrotherapeutic Apparatus · Healthcare · Listed on NYSE
Overall: 5.4 out of 10, Mixed fundamentals
- Growth: 4.3/10
- Profitability: 4.6/10
- Financial health: 4.5/10
- Earnings quality: 7.8/10
- Valuation: 7.5/10
Scores are calculated from Conmed Corporation’s SEC filings, using the 12 months through 2025-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10